Status:
COMPLETED
Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.
Lead Sponsor:
University Hospital, Rouen
Conditions:
Bullous Pemphigoid (BP)
Eligibility:
All Genders
18+ years
Brief Summary
Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. The incidence of BP has increased due to increased life expectancy, particularly in developed countries, which can be associa...
Detailed Description
The patient's physical and psychological state can be seriously affected by the disease itself or by the side effects of treatment. These effects could lead to a decrease in the patient's functional c...
Eligibility Criteria
Inclusion
- Adult Patient
- Patients: Bullous Pemphigoid: Newly diagnosed by:
- Rash suggestive of Bullous Pemphigoid
- Histology: Subepidermal bulla or margination of eosinophils along the dermoepidermal junction (DEJ)
- Controls: Patient with Basal Cell Carcinoma, Squamous Cell Carcinoma, Seborrheic Keratosis, Actinic Keratosis, or Other Benign Skin Tumor. We selected the control group from these patients because these dermatological conditions do not affect sleep quality.
- Mini Mental Status Examination (MMS) score \> 20
- No Formulated Opposition
Exclusion
- Protected Adult
- Advanced Dementia Syndrome
Key Trial Info
Start Date :
August 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT07188402
Start Date
August 4 2020
End Date
January 1 2024
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Rouen Hospital
Rouen, France, 76031